Background Immunoglobulin A nephropathy (IgAN) is a common primary glomerulonephropathy. There is evidence that mesangial C3 deposition plays a role in the development of the disease. The aim of this study was to examine the effect of C3 deposition on the prognosis of IgAN patients. Method The study included 1135 patients with biopsy-confirmed IgAN from the database of the Turkish Nephrology Association Glomerular Diseases Working Group (TSN-GOLD). Patients were excluded from the study if they were aged < 18 or > 75 years or if C3 staining had not been performed in the immunofluorescent analysis. C3 deposition was defined as an immunofluorescence intensity of C3 ≥ 2 + within the mesangium. The primary endpoints were the development of end-stage renal disease, a 30% decrease in glomerular filtration rate compared to the basal value or an elevation in proteinuria to a nephrotic level (3.5 gr/day). Results Mesangial C3 deposition was observed in 603 (53.1%) patients. No statistically significant difference was found at baseline between the groups with and without mesangial C3 deposition, as for age, sex, BMI, proteinuria level, or the presence of hypertension. In the follow-up period with a mean duration of 78 months, no significant difference was found between the two groups regarding the primary endpoints (p = 0.43). A significant correlation between C3 deposition and segmental glomerulosclerosis (S1) according to the Oxford MEST-C classification was found (p = 0.001). Conclusion Although a correlation was observed between mesangial C3 deposition and the S1 MEST-C classification, mesangial C3 deposition was not a prognostic factor in IgAN. Graphical abstract
5 October 2022 in Therapeutic Apheresis and Dialysis
Amaç: Bu çalışmanın amacı; hastanemizde istenen iç hastalıkları konsültasyonlarının retrospektif olarak incelenmesi ve konsültas-yon istemlerindeki eksikliklerin saptanmasıdır. Materyal ve Metot: 01.09.2017 – 31.10.2017 tarihleri arasında acil servis ve diğer yatan hasta kliniklerinden istenen iç hastalıkları konsültasyonları kayıtlar üzerinden retrospektif olarak incelendi. Hastaların demografik verileri ve konsültasyon istem metinleri kaydedildi. Dört soru ile konsültasyon metinleri yeterlilik açısından değerlendirildi ve puanlandı.Bulgular: 2 aylık sürede toplam 416 konsültasyon cevaplanmıştı. 172 acil servis, 244 diğer servislerdi. Yaş ortalaması acil servis için 62,7, diğer servisler için ise 61,8 idi. Nefroloji her iki grupta da en sık konsültasyon istenen iç hastalıkları yan dalı idi. Konsültasyonların %68 gibi büyük bir çoğunluğu ilk 1 saat içeris-inde sonuçlandırılmıştı. Hastaların %53,5’i için yatış kararı verild-iği görüldü. Her iki grupta da değerlendirme puanlarına bakıldığın-da konsültasyon istem metinlerinin yetersiz olduğu görüldü.Sonuç: Konsültasyon istem metinleri genel olarak yetersiz olup ilgili hekimleri yeterli olarak bilgilendirmemektedir. Danışılan hasta hakkında yeterli bilgi sahibi olmayan konsültan hekimin hasta hakkında doğru karar vermesi zorlaşmaktadır. Bu sebeple konsültasyon istem metinlerinin düzeltilmesi çok önemlidir.
IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. We assessed whether the Ratio of Globally Sclerotic Glomeruli (RoGSG) on diagnostic biopsy predicts subsequent kidney outcomes in a nationwide, multi‑center registry. Among 326 adults with idiopathic IgAN (mean age 39.1 ± 12.8 years; 60.1% male), 43 patients (13.2%) met a 5 year composite outcome defined as any of: doubling of serum creatinine or ≥ 50% decline in eGFR from baseline, eGFR < 15 mL/min/1.73 m 2 , or initiation of kidney replacement therapy. Receiver operating characteristic analysis identified a RoGSG cutoff of 28.86% for predicting the composite outcome (AUC 0.917, 95% CI 0.885–0.949; sensitivity 93.0%; specificity 84.5%). Using this threshold, 47.6% of patients with RoGSG ≥ 28.86% versus 1.2% with RoGSG < 28.86% reached the composite outcome. In multivariable models adjusted for clinical and pathologic covariates, high RoGSG, grade 2 tubular atrophy/interstitial fibrosis, and non‑response to initial immunosuppression were independent predictors of adverse outcomes. The prognostic association of RoGSG persisted in key subgroups, including those with nephrotic syndrome and those with initial treatment response. These findings support RoGSG as a readily available histopathologic marker that may improve risk stratification in IgAN; however, prospective studies and external validation in independent cohorts are required before any clinical adoption.
16 March 2023 in Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi
Objective: This study aimed to evaluate treatment adherence and rational drug use in hemodialysis patients and investigate predictive factors on dialysis adequacy. Materıals and Methods: This is a cross-sectional descriptive study. The data were obtained by examining face-to-face questionnaires and patient files. The Hospitalized Patient Questionnaire and the End Stage Kidney Disease Compliance Questionnaire (ESRD-AQ) were administered to the patients. Kt/V was used for dialysis proficiency. By examining the obtained data, the variables that can be associated with the Kt/V value were investigated. Results: A total of 145 patients were included in the study. Sixty nine percent of the participants were over 51 years of age and 54.5% were male. Median Kt/V level was 1.38 (Q1=1.25; Q3=1.54). As for the medications, those with Kt∕V≥1.2 were found to be using more antihypertensive agents, folic acid, vitamin B12, and vitamin C but less levocarnitine concerning the group with Kt/V<1.2 (p<0.05). The Median Score on the End-Stage Renal Failure Adherence Questionnaire was 1150 (Q1=1050; Q3=1200). Total Adherence Score was found to be statistically significantly higher in the group with Kt/V≥1.2 (p<0.05). Conclusıon: It was determined that the level of treatment adherence of the patients participating in the study were considerably high. The probability of receiving adequate dialysis increased as total adherence scores increased. The knowledge level of patients on rational drug use affects adherence. In this study, folic acid, vitamin C, and levocarnitine were associated with dialysis adequacy.
Background: Finerenone is associated with a lower, yet clinically relevant, risk of hyperkalemia compared with steroidal mineralocorticoid receptor antagonists in diabetic kidney disease (DKD) trials. However, real-world data on hyperkalemia and its associated factors are lacking. Methodology: FINE-TURK is a national, observational cohort of DKD patients who were initiated on finerenone. Eligible adults were included; demographic, clinical, and laboratory data were evaluated. The primary outcome (PO) was hyperkalemia risk signal (potassium ≥ 5.0 mEq/L), and the secondary outcome (SO) was clinically meaningful hyperkalemia (potassium ≥ 5.5 mEq/L). Multivariate logistic regression (LR) was used to define features associated with both PO and SO. LR, random forest (RF), gradient boosting, and CatBoost classifiers were used to define important features associated with the PO. Results: 699 patients were included. 259 (37.1%) reached the PO, and 51 (7.3%) reached the SO. Baseline potassium and estimated glomerular filtration rate (eGFR) were the most important variables associated with both outcomes and were consistently identified as the top features across all models. Thiazide use, presence of diabetic retinopathy, and diabetes duration were also associated with the PO. LR demonstrated the highest recall; random forest achieved the highest precision in performance. Discussion: Real-world data suggest that the risk of clinically meaningful hyperkalemia is similar to that in the clinical trials. In parallel with the safety analysis of clinical trials, baseline potassium and eGFR were consistently the most important factors associated with hyperkalemia risk.